Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK...
Gespeichert in:
| Veröffentlicht in: | Oncotarget 2017-10, Vol.8 (46), p.81285-81294 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 81294 |
|---|---|
| container_issue | 46 |
| container_start_page | 81285 |
| container_title | Oncotarget |
| container_volume | 8 |
| creator | Qu, Lihui Lu, Yingying Ying, Meike Li, Bingjue Weng, Chunhua Xie, Zhoutao Liang, Ludan Lin, Chuan Yang, Xian Feng, Shi Wang, Yucheng Shen, Xiujin Zhou, Qin Chen, Ying Chen, Zhimin Wu, Jianyong Lin, Weiqiang Shen, Yi Qin, Jing Xu, Hang Xu, Feng Wang, Junwen Chen, Jianghua Jiang, Hong Huang, Hongfeng |
| description | Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients. |
| doi_str_mv | 10.18632/oncotarget.18150 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5655282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1961849813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-e25ec47d428a6642b58652d4e7b037b7dd73ca9c1c8c6d091f29fb804f73e4873</originalsourceid><addsrcrecordid>eNpVUctKxDAUDaLoMPoBbiRLN6PNq0k2wjD4ggFd6MJVSNPbsdI2nSQV_HuDb-8ml5t7zknOQeiYFGdElYye-8H5ZMMGUh4QUeygGdFcL6gQbPdPf4COYnwpcgkuFdX76IBqQhhTcoYeH6wLvmv7KeLaR8ABtlMboIch4cpGqLEfcHoGvHq6Z0uBNzD49DYCboe8O9gOp2CHOHY2A0ab2gyMh2ivsV2Eo69zjh6vLh9WN4v13fXtarleOCbKtAAqwHFZc6psWXJaCVUKWnOQVcFkJetaMme1I065si40aahuKlXwRjLgSrI5uvjkHaeqh9pl7WA7M4a2t-HNeNua_zdD-2w2_tWIUgiqaCY4_SIIfjtBTKZvo4Mu_wb8FA3RJVFcq-zWHJHP1exXjAGaHxlSmI9EzG8i5iORjDn5-74fxLf_7B2rh4tw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1961849813</pqid></control><display><type>article</type><title>Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Qu, Lihui ; Lu, Yingying ; Ying, Meike ; Li, Bingjue ; Weng, Chunhua ; Xie, Zhoutao ; Liang, Ludan ; Lin, Chuan ; Yang, Xian ; Feng, Shi ; Wang, Yucheng ; Shen, Xiujin ; Zhou, Qin ; Chen, Ying ; Chen, Zhimin ; Wu, Jianyong ; Lin, Weiqiang ; Shen, Yi ; Qin, Jing ; Xu, Hang ; Xu, Feng ; Wang, Junwen ; Chen, Jianghua ; Jiang, Hong ; Huang, Hongfeng</creator><creatorcontrib>Qu, Lihui ; Lu, Yingying ; Ying, Meike ; Li, Bingjue ; Weng, Chunhua ; Xie, Zhoutao ; Liang, Ludan ; Lin, Chuan ; Yang, Xian ; Feng, Shi ; Wang, Yucheng ; Shen, Xiujin ; Zhou, Qin ; Chen, Ying ; Chen, Zhimin ; Wu, Jianyong ; Lin, Weiqiang ; Shen, Yi ; Qin, Jing ; Xu, Hang ; Xu, Feng ; Wang, Junwen ; Chen, Jianghua ; Jiang, Hong ; Huang, Hongfeng</creatorcontrib><description>Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.18150</identifier><identifier>PMID: 29113387</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Clinical Research Paper</subject><ispartof>Oncotarget, 2017-10, Vol.8 (46), p.81285-81294</ispartof><rights>Copyright: © 2017 Qu et al. 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-e25ec47d428a6642b58652d4e7b037b7dd73ca9c1c8c6d091f29fb804f73e4873</citedby><cites>FETCH-LOGICAL-c356t-e25ec47d428a6642b58652d4e7b037b7dd73ca9c1c8c6d091f29fb804f73e4873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655282/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655282/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29113387$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qu, Lihui</creatorcontrib><creatorcontrib>Lu, Yingying</creatorcontrib><creatorcontrib>Ying, Meike</creatorcontrib><creatorcontrib>Li, Bingjue</creatorcontrib><creatorcontrib>Weng, Chunhua</creatorcontrib><creatorcontrib>Xie, Zhoutao</creatorcontrib><creatorcontrib>Liang, Ludan</creatorcontrib><creatorcontrib>Lin, Chuan</creatorcontrib><creatorcontrib>Yang, Xian</creatorcontrib><creatorcontrib>Feng, Shi</creatorcontrib><creatorcontrib>Wang, Yucheng</creatorcontrib><creatorcontrib>Shen, Xiujin</creatorcontrib><creatorcontrib>Zhou, Qin</creatorcontrib><creatorcontrib>Chen, Ying</creatorcontrib><creatorcontrib>Chen, Zhimin</creatorcontrib><creatorcontrib>Wu, Jianyong</creatorcontrib><creatorcontrib>Lin, Weiqiang</creatorcontrib><creatorcontrib>Shen, Yi</creatorcontrib><creatorcontrib>Qin, Jing</creatorcontrib><creatorcontrib>Xu, Hang</creatorcontrib><creatorcontrib>Xu, Feng</creatorcontrib><creatorcontrib>Wang, Junwen</creatorcontrib><creatorcontrib>Chen, Jianghua</creatorcontrib><creatorcontrib>Jiang, Hong</creatorcontrib><creatorcontrib>Huang, Hongfeng</creatorcontrib><title>Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.</description><subject>Clinical Research Paper</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVUctKxDAUDaLoMPoBbiRLN6PNq0k2wjD4ggFd6MJVSNPbsdI2nSQV_HuDb-8ml5t7zknOQeiYFGdElYye-8H5ZMMGUh4QUeygGdFcL6gQbPdPf4COYnwpcgkuFdX76IBqQhhTcoYeH6wLvmv7KeLaR8ABtlMboIch4cpGqLEfcHoGvHq6Z0uBNzD49DYCboe8O9gOp2CHOHY2A0ab2gyMh2ivsV2Eo69zjh6vLh9WN4v13fXtarleOCbKtAAqwHFZc6psWXJaCVUKWnOQVcFkJetaMme1I065si40aahuKlXwRjLgSrI5uvjkHaeqh9pl7WA7M4a2t-HNeNua_zdD-2w2_tWIUgiqaCY4_SIIfjtBTKZvo4Mu_wb8FA3RJVFcq-zWHJHP1exXjAGaHxlSmI9EzG8i5iORjDn5-74fxLf_7B2rh4tw</recordid><startdate>20171006</startdate><enddate>20171006</enddate><creator>Qu, Lihui</creator><creator>Lu, Yingying</creator><creator>Ying, Meike</creator><creator>Li, Bingjue</creator><creator>Weng, Chunhua</creator><creator>Xie, Zhoutao</creator><creator>Liang, Ludan</creator><creator>Lin, Chuan</creator><creator>Yang, Xian</creator><creator>Feng, Shi</creator><creator>Wang, Yucheng</creator><creator>Shen, Xiujin</creator><creator>Zhou, Qin</creator><creator>Chen, Ying</creator><creator>Chen, Zhimin</creator><creator>Wu, Jianyong</creator><creator>Lin, Weiqiang</creator><creator>Shen, Yi</creator><creator>Qin, Jing</creator><creator>Xu, Hang</creator><creator>Xu, Feng</creator><creator>Wang, Junwen</creator><creator>Chen, Jianghua</creator><creator>Jiang, Hong</creator><creator>Huang, Hongfeng</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171006</creationdate><title>Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients</title><author>Qu, Lihui ; Lu, Yingying ; Ying, Meike ; Li, Bingjue ; Weng, Chunhua ; Xie, Zhoutao ; Liang, Ludan ; Lin, Chuan ; Yang, Xian ; Feng, Shi ; Wang, Yucheng ; Shen, Xiujin ; Zhou, Qin ; Chen, Ying ; Chen, Zhimin ; Wu, Jianyong ; Lin, Weiqiang ; Shen, Yi ; Qin, Jing ; Xu, Hang ; Xu, Feng ; Wang, Junwen ; Chen, Jianghua ; Jiang, Hong ; Huang, Hongfeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-e25ec47d428a6642b58652d4e7b037b7dd73ca9c1c8c6d091f29fb804f73e4873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Clinical Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Qu, Lihui</creatorcontrib><creatorcontrib>Lu, Yingying</creatorcontrib><creatorcontrib>Ying, Meike</creatorcontrib><creatorcontrib>Li, Bingjue</creatorcontrib><creatorcontrib>Weng, Chunhua</creatorcontrib><creatorcontrib>Xie, Zhoutao</creatorcontrib><creatorcontrib>Liang, Ludan</creatorcontrib><creatorcontrib>Lin, Chuan</creatorcontrib><creatorcontrib>Yang, Xian</creatorcontrib><creatorcontrib>Feng, Shi</creatorcontrib><creatorcontrib>Wang, Yucheng</creatorcontrib><creatorcontrib>Shen, Xiujin</creatorcontrib><creatorcontrib>Zhou, Qin</creatorcontrib><creatorcontrib>Chen, Ying</creatorcontrib><creatorcontrib>Chen, Zhimin</creatorcontrib><creatorcontrib>Wu, Jianyong</creatorcontrib><creatorcontrib>Lin, Weiqiang</creatorcontrib><creatorcontrib>Shen, Yi</creatorcontrib><creatorcontrib>Qin, Jing</creatorcontrib><creatorcontrib>Xu, Hang</creatorcontrib><creatorcontrib>Xu, Feng</creatorcontrib><creatorcontrib>Wang, Junwen</creatorcontrib><creatorcontrib>Chen, Jianghua</creatorcontrib><creatorcontrib>Jiang, Hong</creatorcontrib><creatorcontrib>Huang, Hongfeng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qu, Lihui</au><au>Lu, Yingying</au><au>Ying, Meike</au><au>Li, Bingjue</au><au>Weng, Chunhua</au><au>Xie, Zhoutao</au><au>Liang, Ludan</au><au>Lin, Chuan</au><au>Yang, Xian</au><au>Feng, Shi</au><au>Wang, Yucheng</au><au>Shen, Xiujin</au><au>Zhou, Qin</au><au>Chen, Ying</au><au>Chen, Zhimin</au><au>Wu, Jianyong</au><au>Lin, Weiqiang</au><au>Shen, Yi</au><au>Qin, Jing</au><au>Xu, Hang</au><au>Xu, Feng</au><au>Wang, Junwen</au><au>Chen, Jianghua</au><au>Jiang, Hong</au><au>Huang, Hongfeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2017-10-06</date><risdate>2017</risdate><volume>8</volume><issue>46</issue><spage>81285</spage><epage>81294</epage><pages>81285-81294</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Tacrolimus (FK506) and cyclosporine A (CsA) are widely used to protect graft function after renal transplantation. The aim of the present study is to determine whether the single nucleotide polymorphism of CYP3A5 is a predictive index of FK506 dose requirement, and also the selection yardstick of FK506 or CsA treatment.We tested archival peripheral blood of 218 kidney recipients for CYP3A5 genotyping with PCR-SSP. Meanwhile, the dose of FK506 and CsA was recorded, blood concentration of the drugs was measured, and graft outcome was monitored.These results indicate that CYP3A5*AA/AG carriers need higher FK506 dose than CYP3A5*GG homozygote to achieve the target blood concentration. For CYP3A5*GG carriers, taking FK506 or CsA are both advisable. CYP3A5*AA/AG carriers preferred to CsA treatment depending on the graft outcomes and drug costs. CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>29113387</pmid><doi>10.18632/oncotarget.18150</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1949-2553 |
| ispartof | Oncotarget, 2017-10, Vol.8 (46), p.81285-81294 |
| issn | 1949-2553 1949-2553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5655282 |
| source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free E- Journals |
| subjects | Clinical Research Paper |
| title | Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A22%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tacrolimus%20dose%20requirement%20based%20on%20the%20CYP3A5%20genotype%20in%20renal%20transplant%20patients&rft.jtitle=Oncotarget&rft.au=Qu,%20Lihui&rft.date=2017-10-06&rft.volume=8&rft.issue=46&rft.spage=81285&rft.epage=81294&rft.pages=81285-81294&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.18150&rft_dat=%3Cproquest_pubme%3E1961849813%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1961849813&rft_id=info:pmid/29113387&rfr_iscdi=true |